LeMaitre Vascular, Inc. (LMAT)
USD 90.34
(-0.65%)
USD 90.34
(-0.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 30.1 Million USD | 45.89% |
| 2022 | 20.63 Million USD | -23.31% |
| 2021 | 26.9 Million USD | 26.8% |
| 2020 | 21.22 Million USD | 18.32% |
| 2019 | 17.93 Million USD | -21.83% |
| 2018 | 22.94 Million USD | 33.57% |
| 2017 | 17.17 Million USD | 62.2% |
| 2016 | 10.59 Million USD | 36.5% |
| 2015 | 7.75 Million USD | 98.16% |
| 2014 | 3.91 Million USD | 22.27% |
| 2013 | 3.2 Million USD | 24.54% |
| 2012 | 2.57 Million USD | 19.97% |
| 2011 | 2.14 Million USD | -64.36% |
| 2010 | 6.01 Million USD | 276.28% |
| 2009 | 1.59 Million USD | 148.22% |
| 2008 | -3.31 Million USD | -12.95% |
| 2007 | -2.93 Million USD | -150.34% |
| 2006 | -1.17 Million USD | -2230.91% |
| 2005 | 55 Thousand USD | -94.07% |
| 2004 | 927 Thousand USD | 517.57% |
| 2003 | -222 Thousand USD | -145.96% |
| 2002 | 483 Thousand USD | 179.83% |
| 2001 | -605 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 11.14 Million USD | -5.79% |
| 2024 Q2 | 11.82 Million USD | 19.61% |
| 2024 Q1 | 9.88 Million USD | 16.8% |
| 2023 FY | 30.1 Million USD | 45.89% |
| 2023 Q1 | 6.04 Million USD | 7.34% |
| 2023 Q2 | 8.09 Million USD | 34.07% |
| 2023 Q3 | 7.5 Million USD | -7.36% |
| 2023 Q4 | 8.46 Million USD | 12.84% |
| 2022 FY | 20.63 Million USD | -23.31% |
| 2022 Q2 | 3.51 Million USD | -41.79% |
| 2022 Q1 | 6.03 Million USD | -2.22% |
| 2022 Q4 | 5.62 Million USD | 3.13% |
| 2022 Q3 | 5.45 Million USD | 55.22% |
| 2021 Q2 | 8.29 Million USD | 39.97% |
| 2021 Q3 | 6.5 Million USD | -21.63% |
| 2021 FY | 26.9 Million USD | 26.8% |
| 2021 Q4 | 6.17 Million USD | -5.06% |
| 2021 Q1 | 5.92 Million USD | -15.7% |
| 2020 Q3 | 7.51 Million USD | 114.66% |
| 2020 FY | 21.22 Million USD | 18.32% |
| 2020 Q4 | 7.03 Million USD | -6.39% |
| 2020 Q1 | 3.17 Million USD | -31.19% |
| 2020 Q2 | 3.5 Million USD | 10.27% |
| 2019 Q1 | 3.51 Million USD | -41.69% |
| 2019 Q3 | 5.18 Million USD | 12.11% |
| 2019 Q4 | 4.61 Million USD | -11.01% |
| 2019 FY | 17.93 Million USD | -21.83% |
| 2019 Q2 | 4.62 Million USD | 31.63% |
| 2018 Q3 | 4.31 Million USD | -50.7% |
| 2018 Q1 | 3.85 Million USD | -10.06% |
| 2018 FY | 22.94 Million USD | 33.57% |
| 2018 Q4 | 6.02 Million USD | 39.66% |
| 2018 Q2 | 8.75 Million USD | 127.12% |
| 2017 FY | 17.17 Million USD | 62.2% |
| 2017 Q4 | 4.28 Million USD | -15.03% |
| 2017 Q3 | 5.04 Million USD | 8.85% |
| 2017 Q2 | 4.63 Million USD | 43.9% |
| 2017 Q1 | 3.21 Million USD | 23.95% |
| 2016 FY | 10.59 Million USD | 36.5% |
| 2016 Q3 | 3.22 Million USD | 24.29% |
| 2016 Q2 | 2.59 Million USD | 19.94% |
| 2016 Q4 | 2.59 Million USD | -19.57% |
| 2016 Q1 | 2.16 Million USD | -14.39% |
| 2015 Q4 | 2.53 Million USD | 20.94% |
| 2015 FY | 7.75 Million USD | 98.16% |
| 2015 Q3 | 2.09 Million USD | 18.39% |
| 2015 Q2 | 1.76 Million USD | 29.07% |
| 2015 Q1 | 1.36 Million USD | -28.55% |
| 2014 Q3 | 934 Thousand USD | -26.57% |
| 2014 Q4 | 1.91 Million USD | 105.14% |
| 2014 FY | 3.91 Million USD | 22.27% |
| 2014 Q1 | -207 Thousand USD | -127.75% |
| 2014 Q2 | 1.27 Million USD | 714.49% |
| 2013 Q3 | 781 Thousand USD | -12.15% |
| 2013 Q4 | 746 Thousand USD | -4.48% |
| 2013 Q1 | 846 Thousand USD | 21.2% |
| 2013 FY | 3.2 Million USD | 24.54% |
| 2013 Q2 | 889 Thousand USD | 5.08% |
| 2012 Q3 | 663 Thousand USD | -19.54% |
| 2012 Q4 | 698 Thousand USD | 5.28% |
| 2012 Q2 | 824 Thousand USD | 113.47% |
| 2012 Q1 | 386 Thousand USD | 11.56% |
| 2012 FY | 2.57 Million USD | 19.97% |
| 2011 FY | 2.14 Million USD | -64.36% |
| 2011 Q1 | 64 Thousand USD | -96.74% |
| 2011 Q2 | 519 Thousand USD | 710.94% |
| 2011 Q3 | 1.21 Million USD | 133.91% |
| 2011 Q4 | 346 Thousand USD | -71.5% |
| 2010 Q3 | 1.51 Million USD | 0.4% |
| 2010 Q4 | 1.96 Million USD | 29.47% |
| 2010 FY | 6.01 Million USD | 276.28% |
| 2010 Q1 | 1.02 Million USD | -19.54% |
| 2010 Q2 | 1.51 Million USD | 47.99% |
| 2009 Q2 | 925 Thousand USD | 149.18% |
| 2009 Q1 | -1.88 Million USD | -702.88% |
| 2009 FY | 1.59 Million USD | 148.22% |
| 2009 Q4 | 1.26 Million USD | -1.25% |
| 2009 Q3 | 1.28 Million USD | 38.92% |
| 2008 FY | -3.31 Million USD | -12.95% |
| 2008 Q2 | -926 Thousand USD | 63.88% |
| 2008 Q3 | -136 Thousand USD | 85.31% |
| 2008 Q4 | 312 Thousand USD | 329.41% |
| 2008 Q1 | -2.56 Million USD | -117.66% |
| 2007 FY | -2.93 Million USD | -150.34% |
| 2007 Q4 | -1.17 Million USD | 13.0% |
| 2007 Q2 | 227 Thousand USD | 136.09% |
| 2007 Q3 | -1.35 Million USD | -696.48% |
| 2007 Q1 | -629 Thousand USD | 6.68% |
| 2006 Q1 | 370 Thousand USD | 802.44% |
| 2006 Q4 | -674 Thousand USD | -403.6% |
| 2006 FY | -1.17 Million USD | -2230.91% |
| 2006 Q3 | 222 Thousand USD | 120.37% |
| 2006 Q2 | -1.09 Million USD | -394.59% |
| 2005 Q3 | -42 Thousand USD | -940.0% |
| 2005 Q4 | 41 Thousand USD | 197.62% |
| 2005 Q2 | 5000.00 USD | -90.2% |
| 2005 FY | 55 Thousand USD | -94.07% |
| 2005 Q1 | 51 Thousand USD | -77.92% |
| 2004 FY | 927 Thousand USD | 517.57% |
| 2004 Q4 | 231 Thousand USD | -0.43% |
| 2004 Q1 | 232 Thousand USD | 0.0% |
| 2004 Q3 | 232 Thousand USD | 0.0% |
| 2004 Q2 | 232 Thousand USD | 0.0% |
| 2003 FY | -222 Thousand USD | -145.96% |
| 2002 FY | 483 Thousand USD | 179.83% |
| 2001 FY | -605 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 147.542% |
| AngioDynamics, Inc. | -184.34 Million USD | 116.33% |
| AtriCure, Inc. | -30.43 Million USD | 198.906% |
| Avinger, Inc. | -18.32 Million USD | 264.329% |
| Azenta, Inc. | -14.25 Million USD | 311.159% |
| BioLife Solutions, Inc. | -66.42 Million USD | 145.32% |
| The Cooper Companies, Inc. | 294.2 Million USD | 89.767% |
| Daxor Corporation | 280.64 Thousand USD | -10627.266% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | 298.085% |
| Femasys Inc. | -14.24 Million USD | 311.306% |
| GlucoTrack, Inc. | -7.09 Million USD | 524.193% |
| Harvard Bioscience, Inc. | -3.41 Million USD | 981.552% |
| Hologic, Inc. | 789.5 Million USD | 96.187% |
| ICU Medical, Inc. | -29.65 Million USD | 201.517% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 98.326% |
| KORU Medical Systems, Inc. | -13.74 Million USD | 319.088% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 551.794% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 551.794% |
| Masimo Corporation | 81.5 Million USD | 63.061% |
| Microbot Medical Inc. | -10.74 Million USD | 380.307% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | -158.958% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 68.113% |
| Nephros, Inc. | -1.57 Million USD | 2011.429% |
| NovoCure Limited | -207.04 Million USD | 114.54% |
| NEXGEL, Inc. | -3.15 Million USD | 1053.595% |
| NEXGEL, Inc. | -3.15 Million USD | 1053.595% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 131.75% |
| OraSure Technologies, Inc. | 53.65 Million USD | 43.892% |
| Pro-Dex, Inc. | 2.12 Million USD | -1315.374% |
| Pulse Biosciences, Inc. | -42.21 Million USD | 171.322% |
| Predictive Oncology Inc. | -13.98 Million USD | 315.282% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | 1120.032% |
| QuidelOrtho Corporation | -10.1 Million USD | 398.069% |
| Repligen Corporation | 41.57 Million USD | 27.592% |
| Sanara MedTech Inc. | -4.3 Million USD | 799.596% |
| STAAR Surgical Company | 21.34 Million USD | -41.027% |
| Sharps Technology, Inc. | -9.84 Million USD | 405.894% |
| Utah Medical Products, Inc. | 16.63 Million USD | -80.974% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 122.807% |
| Jin Medical International Ltd. | 2.87 Million USD | -945.955% |